Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Mitsuru WatanabeYuri NakamuraZuzanna MichalakNoriko IsobeChristian BarroDavid LeppertTakuya MatsushitaFumie HayashiRyo YamasakiJens KuhleJun-Ichi Kira

Published in: Neurology (2019)

sGFAP and sNfL are likely to be good biomarkers of disease activity and disability, and the sGFAP/sNfL quotient at relapse is a potential diagnostic marker for NMOSD.

Keyphrases

disease activity
systemic lupus erythematosus
rheumatoid arthritis
rheumatoid arthritis patients
ankylosing spondylitis
multiple sclerosis
juvenile idiopathic arthritis
cerebrospinal fluid
free survival